PRVB News and Press, Provention Bio Inc. From 05/18/20

OLDWICK, N.J. and TAMPERE, Finland , May 18, 2020 /PRNewswire/ --  Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease and its licensor, Vactech Oy (Vactech), a Finnish biotechnology compan...

Provention Bio, Inc. (PRVB) Q1 2020 Earnings Conference Call May 7, 2020 04:30 PM ET Company Participants Sam Martin - IR, Argot Partners Andrew Drechsler - CFO Ashleigh Palmer - Co-Founder and CEO Francisco Leon - Co-Founder and CSO Jason Hoitt - CCO Conference Call Parti...

Image source: The Motley Fool. Provention Bio, Inc   (NASDAQ: PRVB) Q1 2020 Earnings Call May 8, 2020 , 9:30 p.m. ET Operator Continue reading

Provention Bio (NASDAQ: PRVB ): Q1 GAAP EPS of -$0.26 misses by $0.01 . More news on: Provention Bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

OLDWICK, N.J. , April 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its first quarter 2020 financial results on Thurs...

Provention Bio ( PRVB ) is a small-cap biotech company focused on developing drugs to combat autoimmune diseases – in particular, Type 1 diabetes (T1D). At the time of writing, it trades at a share price of $9.85, giving a market cap of $470m and an enterprise value of roughly $385m. ...

Provention Bio (NASDAQ: PRVB ) has initiated the rolling submission of its Biologic License Application (BLA) to the FDA for teplizumab (PRV-031), an anti-CD3 monoclonal antibody for the delay or prevention of Type 1 Diabetes (T1D) in at-risk individuals. More news on: Provention Bio, In...

OLDWICK, N.J. , April 16, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the initiation of the rolling submission of the Company's Biologic License...

This article was highlighted for PRO subscribers, Seeking Alpha's service for professional investors. Find out how you can get the best content on Seeking Alpha here . The ability of Provention Bio's ( PRVB ) lead drug candidate, teplizumab, to delay the onset and potentially prevent Type...

Pharmaceutical giant Eli Lilly (NYSE: LLY) has been doing its part in the battle against COVID-19. It teamed up with the Indiana State Department of Health to make more testing for the disease available to people in its home state, and plans to start offering drive-thru testing for COVID...